Skip to main content
. 2020 Aug 18;55(10):891–902. doi: 10.1097/MCG.0000000000001409

FIGURE 4.

FIGURE 4

Cumulative all-cause health care costs among patients with NAFLD/NASH by liver disease severity stage. aNAFLD/NASH study cohort comprises overall NAFLD/NASH patients until progression to a more severe stage, at which follow-up is censored. *Percent change denotes the increase in mean costs from year −2 to year 5. †Percent change denotes the increase in mean costs from year −1 to year 1. AdvLD indicates advanced liver diseases; CC, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.